CompletedPhase 2NCT04013672

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

Studying Astrocytoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
David Peereboom
Principal Investigator
David Peereboom, MD, MD
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Intervention
Pembrolizumab(drug)
Enrollment
41 target
Eligibility
18 years · All sexes
Timeline
2020 – 2022

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04013672 on ClinicalTrials.gov

Other trials for Astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Astrocytoma →

← Back to all trials